Welireg™ Is Available From Onco360
WELIREG™ (belzutifan) is a hypoxia-inducible factor inhibitor indicated for treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.
Dosage and Administration1
The recommended dose for WELIREG is 120 mg (40 mg tablet x 3) orally once daily.
Dosage Forms and Strengths
WELIREG is available in 40 mg tablets (NDC 0006-5331-01) in 90 count pill bottles.
For full prescribing details visit: Welireg
1WELIREG prescribing information: Merck & Co., Inc. Accessed 7.21. WELIREG © copyright 2021 Merck Sharp & Dohme Corp., a subsidary of Merck & Co., Inc. All rights reserved